福安药业
(300194)
| 流通市值：44.16亿 | | | 总市值：54.25亿 |
| 流通股本：9.68亿 | | | 总股本：11.90亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,315,372,998.73 | 920,507,640.79 | 467,678,211.11 | 2,391,468,105.37 |
| 营业收入 | 1,315,372,998.73 | 920,507,640.79 | 467,678,211.11 | 2,391,468,105.37 |
| 二、营业总成本 | 1,256,272,424.41 | 859,575,205.52 | 424,656,082.74 | 2,124,236,673.71 |
| 营业成本 | 832,940,616.62 | 578,672,967.4 | 277,152,681 | 1,124,997,486.04 |
| 税金及附加 | 19,625,240 | 12,978,822.67 | 6,468,368 | 30,752,914.2 |
| 销售费用 | 144,440,403.14 | 99,536,304.86 | 58,120,765.7 | 563,426,225.62 |
| 管理费用 | 157,883,677.54 | 107,398,617.59 | 53,478,613.35 | 258,776,299.62 |
| 研发费用 | 102,922,124.68 | 62,513,285.14 | 30,330,798.21 | 153,223,657.68 |
| 财务费用 | -1,539,637.57 | -1,524,792.14 | -895,143.52 | -6,939,909.45 |
| 其中:利息费用 | 17,096,399.02 | 11,295,353.72 | 1,919,204.41 | 23,338,101.62 |
| 其中:利息收入 | 18,758,005.77 | 12,652,690.37 | 6,155,799.35 | 29,808,752.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 483,917.81 | 444,849.31 | 60,712.33 | -32,735,646.45 |
| 加:投资收益 | 101,927,003.45 | 60,523,130.09 | 30,950,153.11 | 76,987,951.6 |
| 资产处置收益 | -42,703.27 | -35,989.89 | 0 | 9,036.8 |
| 资产减值损失(新) | -12,388,006.59 | -9,449,459.93 | -3,192,658.29 | -34,741,850.61 |
| 信用减值损失(新) | -5,172,835.27 | -7,090,729.23 | -3,842,431.67 | -3,792,040.34 |
| 其他收益 | 25,135,164.73 | 14,462,727.55 | 6,157,771.01 | 47,887,951.1 |
| 四、营业利润 | 169,043,115.18 | 119,786,963.17 | 73,155,674.86 | 320,846,833.76 |
| 加:营业外收入 | 1,109,205.2 | 534,005.62 | 132,705.57 | 4,697,109.41 |
| 减:营业外支出 | 2,269,832.89 | 1,910,362.12 | 800,760.47 | 13,347,389.08 |
| 五、利润总额 | 167,882,487.49 | 118,410,606.67 | 72,487,619.96 | 312,196,554.09 |
| 减:所得税费用 | 2,013,633.74 | 5,669,049.53 | 3,689,880.99 | 34,025,539.11 |
| 六、净利润 | 165,868,853.75 | 112,741,557.14 | 68,797,738.97 | 278,171,014.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 165,868,853.75 | 112,741,557.14 | 68,797,738.97 | 278,171,014.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 166,262,735.72 | 113,120,774.38 | 69,049,030.79 | 279,837,280.89 |
| 少数股东损益 | -393,881.97 | -379,217.24 | -251,291.82 | -1,666,265.91 |
| 扣除非经常损益后的净利润 | 148,497,322.24 | 104,050,392.23 | 65,684,805.91 | 258,500,650.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.1 | 0.06 | 0.24 |
| (二)稀释每股收益 | 0.14 | 0.1 | 0.06 | 0.24 |
| 八、其他综合收益 | -30,787,570.75 | -16,143,070.73 | -21,233,854.46 | 30,781,583.67 |
| 归属于母公司股东的其他综合收益 | -30,787,570.75 | -16,143,070.73 | -21,233,854.46 | 30,781,583.67 |
| 九、综合收益总额 | 135,081,283 | 96,598,486.41 | 47,563,884.51 | 308,952,598.65 |
| 归属于母公司股东的综合收益总额 | 135,475,164.97 | 96,977,703.65 | 47,815,176.33 | 310,618,864.56 |
| 归属于少数股东的综合收益总额 | -393,881.97 | -379,217.24 | -251,291.82 | -1,666,265.91 |
| 公告日期 | 2025-10-28 | 2025-08-27 | 2025-04-24 | 2025-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |